Doug Miller

Doug Miller is the current Chief Financial Officer at Synthetic Genomics. Prior to their current position, Doug served as the VP and Corporate Controller at Halozyme Therapeutics, Inc. from April 2016 to July 2017. Before that, they were the VP Finance for the Medical Systems Segment CFO at CareFusion from November 2012 to July 2015.

From June 2009 to November 2012, Doug Miller worked as a M&A, Integration and Separation Consulting, providing M&A, integration, separation, and accounting consulting services. Doug was also a Partner at PricewaterhouseCoopers from June 1991 to May 2009 where they provided audit, capital markets, and transaction services.

Doug Miller has a MBA from Questrom School of Business at Boston University and a BS in Government from Wesleyan University.

Their manager is Oliver Fetzer, CEO. Some of their coworkers include Rob Brown - Vice President, Research, Rob Cutler - General Counsel, Corporate Secretary, and Margaret Dunbar - Vice President, Intellectual Property.